Compounded semaglutide vs Compounded tirzepatide

Semaglutide and tirzepatide work differently in the body. Semaglutide targets GLP-1 receptors, while tirzepatide targets both GIP and GLP-1 receptors. Both may cause similar digestive side effects, including nausea, vomiting, diarrhea, and constipation, and have important safety considerations. Weight-loss responses can vary between individuals, so a licensed healthcare provider can help determine which treatment, if either, is medically appropriate for you.

How semaglutide and tirzepatide work

To understand the difference between semaglutide and tirzepatide, it helps to start with GLP-1 and GIP. These are hormones involved in the body’s signaling around things such as appetite and digestion. Your cells have proteins called receptors that receive signals from hormones. Think of a receptor as a place where a hormone can deliver its message. When a medication activates a receptor, it can mimic or influence some of the signals associated with that hormone.

Semaglutide activates the GLP-1 receptor. In simple terms, it works through the same receptor pathway used by the hormone GLP-1. Where as tirzepatide activates two receptors: the GLP-1 receptor and the GIP receptor. That is the main biological difference between the two.

Understanding this difference can make the comparison of the two easier to follow. It does not, by itself, tell you which treatment is appropriate for you. Everyone responds to treatment differently. What you experience with semaglutide or tirzepatide may differ from someone else’s experience. A licensed provider can discuss your options with you and help determine which treatment approach may be appropriate for your circumstances.

Side effects of semaglutide vs tirzepatide

Semaglutide and tirzepatide can cause some of the same side effects, particularly digestive ones. These include

• Nausea
• Vomiting
• Diarrhea
• Abdominal pain and constipation.

Not everyone will experience these effects, and they can affect people differently during treatment. Having a particular side effect does not by itself tell you whether semaglutide or tirzepatide is the right treatment for you.

Both medications also have important safety warnings. Their labeled information includes a warning about the potential risk of thyroid C-cell tumors. They should not be used by people with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2 (MEN 2). Neither medication is recommended for people with severe gastroparesis. Tirzepatide's labeled information also lists decreased appetite and dyspepsia among its common adverse reactions.

The main takeaway is that semaglutide and tirzepatide have several side effects and safety considerations in common, but they are different medications.

Compounded semaglutide and compounded tirzepatide at Mondae

If you’re comparing semaglutide and tirzepatide, understanding how each medication works, how they differ, and their key safety considerations can help you have a more informed conversation with a licensed provider through Mondae about whether either treatment may be medically appropriate for you.

You do not need to decide which one is right for you before speaking with a provider. For either option, you can complete a health questionnaire and a licensed provider reviews your information to determine whether treatment is appropriate. If a treatment is prescribed, the provider determines the dosage, titration and duration of treatment. Both treatments are once-weekly injections and require a prescription. If prescribed, a licensed pharmacy dispenses and ships the medication to you.

You can learn more about each option here:

• Compounded semaglutide
• Compounded tirzepatide

If you are unsure which option to consider, or wish to talk more about the options for yourself, the best next step is to discuss the differences with a licensed provider.